AXSM
Axsome Therapeutics, Inc.
Stock
$179.25−2.82 (−1.55%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$71M | −$93M | −$128M | −$145M | −$117M | −$108M | −$78M | −$46M | −$30M | −$26M | −$21M | −$7.4M | −$4.6M |
| Capital expenditures | $700K | $480K | $270K | $582K | $702K | $308K | $46K | $16K | $33K | $10K | $105K | $20K | — |
| Free cash flow | −$72M | −$94M | −$129M | −$146M | −$117M | −$109M | −$79M | −$46M | −$30M | −$26M | −$21M | −$7.5M | — |
| Stock-based compensation | $96M | $94M | $85M | $63M | $38M | $21M | $15M | $6.1M | $1.8M | $2.1M | $2.0M | $803K | $377K |
| Free cash flow margin | −9.3% | −14.7% | −33.4% | −53.8% | −234.3% | — | — | — | — | — | — | — | — |